Confidential Treatment Requested. Confidential portions of this document have been redacted and filed separately with the Commission. ***** Confidential material redacted and filed separately with the Commission. RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • August 23rd, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • London
RESEARCH AND LICENSE AGREEMENT (the “Agreement”) made and entered into as of April 18, 2000 the “Effective Date”), by and between DRK BLUTSPENDEDIENDST BADEN-WURTTENBERG, INSTITUT ULM (the “Licensor”), having an address at Postfach 15 64, U-89005 Ulm, Germany, and XTL BIOPHARMACEUTICALS, LTD. (the “Company”), having an address at Kiryat Weizmann, P.O. Box 370, Rehovot, 76100, Israel.
Confidential Treatment Requested. Confidential portions of this documents have been redacted and separately filed with the Commission. ***** Confidential material redacted and filed separately with the Commission.Confidential Treatment Requested • August 23rd, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
We set out below the amendments to the Agreement (as already amended by Amendment No. 1) and to Amendment No. 1 agreed between Yeda Research and Development Co. Ltd. (“Yeda”) and XTL Biopharmaceuticals, Ltd. (“the Corporation”) following discussions between the parties conducted at the Corporation’s request:
Confidential Treatment Requested. Confidential portions of this document have been redacted and separately filed with the Commission. LICENSE AGREEMENTLicense Agreement • August 23rd, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (this “Agreement”), effective as of June 2, 2004 (the “Effective Date”), is between CUBIST PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware (together with its Affiliates referred to herein as “CUBIST”) and XTL BIOPHARMACEUTICALS LTD., a corporation organized and existing under the laws of Israel (together with its Affiliates referred to herein as “XTL”). XTL and CUBIST are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
Confidential Treatment Requested. Confidential portions of this document have been redacted and separately filed with the Commission. ***** Confidential material redacted and filed separately with the Commission LICENSE AGREEMENTConfidential Treatment Requested • August 23rd, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • California
Effective as of September 12, 2003 ("Effective Date"), THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, a body having corporate powers under the laws of the State of California ("STANFORD"), and XTL Biopharmaceuticals Ltd., a corporation organized under the laws of Israel having a principal place of business at Kiryat Weizmann, P.O. Box 370, Rehovot, 76100 Israel ("LICENSEE"), agree as follows:
CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of this document have been redacted and separately filed with the Commission. ***** Confidential material redacted and filed separately with the Commission.Confidential Treatment • August 23rd, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • New York
LICENSE AGREEMENT dated as of August 17, 2005 (the “Agreement Date”) between VivoQuest, Inc., a Delaware corporation (“VivoQuest”), and XTL Biopharmaceuticals Ltd., an Israeli corporation (“Licensee”).
XTL Biopharmaceuticals Inc. Newton, Massachusetts 02466Asset Purchase Agreement • August 23rd, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • New York
Reference is made to the Asset Purchase Agreement dated as of August 17, 2005 (the “Purchase Agreement”) between XTL Biopharmaceuticals Inc., a Delaware corporation (“Purchaser”) and VivoQuest, Inc. (“Seller”). Capitalized terms used and not otherwise defined in this letter agreement shall have the meanings assigned to them in the Purchase Agreement.
ContractAsset Purchase Agreement • August 23rd, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • New York
ASSET PURCHASE AGREEMENT dated as of August 17, 2005 among VivoQuest, Inc., a Delaware corporation (“Seller”), and XTL Biopharmaceuticals Inc., a Delaware corporation (“Purchaser”).
